Navigation Links
Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
Date:11/6/2011

iseases, including SJIA[5]. ACZ885 works by neutralizing IL-1 beta for a sustained period of time, therefore inhibiting inflammation.

ACZ885 is currently approved in the US and other countries for a different disease state.

DisclaimerThe foregoing release contains forward-looking statements that can be identified by terminology such as "can," "on track," "potentially," "will," "planned," "may," "committed," "potential," or similar expressions, or by express or implied discussions regarding potential new indications or labeling for ACZ885 or regarding potential future revenues from ACZ885. You should not place undue reliance on these statements.  Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with ACZ885 to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that ACZ885 will be submitted or approved for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that ACZ885 will achieve any particular levels of revenue in the future. In particular, management's expectations regarding ACZ885 could be affected by, among other things, unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; competition in general; government, industry and general public pricing pressures; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; unexpected manufacturing issues, the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
2. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
3. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
4. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
5. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
6. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
7. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
8. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
9. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
10. Novartis Class Awarded $250 Million in Punitive Damages
11. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... (PRWEB) May 22, 2013 Mold remediation could ... said that there is a way to cut down the ... on its latest post the details of a method ... money. , Mold could be prevented, My Cleaning Products said. ... company stated that a mold remediation must then be promptly ...
(Date:5/22/2013)... May 22, 2013 The ability ... deciphering the information they encode. There are now ... (deep sequencing of ribosome protected fragments) that dramatically ... , Keynote speakers include Dr. Jonathan Weissman, an ... the Howard Hughes Medical Institute, who will present ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Custom ... to reporting eLearning solution using Tin Can API ... dashboard tool. CLD is a leading developer of ... medical device companies worldwide. , Tin Can ... that helps learners and trainers more accurately measure ...
(Date:5/21/2013)... May 21, 2013 Savoury Systems International ... appointed Dale Braddy to Southeastern USA Sales Broker. Braddy’s ... sales muscle in the Southeast. , In ... brokerage and supplier to food processors and industrial manufacturers. ... in the food industry and has over 25 years ...
Breaking Biology Technology:How to Kill Mold While Saving Thousands of Dollars on Mold Remediation Projects Explained by My Cleaning Products 2Monitoring Protein Synthesis One Codon at a Time Through Ribosome Profiling, a Webinar Hosted by Xtalks 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 3
... Sciences presented their latest biological results supporting the ... compound for the treatment of solid tumors at ... British Columbia. The presentation highlighted advances in the ... piperazines demonstrate potent antiproliferative activity against a variety ...
... Gene Therapy in Cardiac Disease (CUPID Trial) Demonstrated ... Using Gene TransferSAN DIEGO, April 8 Celladon ... a Phase 1/2 trial of MYDICAR(R) (AAV1/SERCA2a), a ... failure, in the April 2009 issue of the ...
... DNA sequencing technology company, announced a definitive agreement ... investment in the company. Prompting its decision was ... reversible terminator chemistry, Lightning Terminators (TM), for ... chemistry as reagent kits to the market as ...
Cached Biology Technology:ImQuest Presentation at Keystone Symposium Focuses on Advancements in Their Cancer Research and Development Program 2The Journal of Cardiac Failure Publishes Results From Celladon Corporation's First-in-Human Phase 1/2 Clinical Trial in Advanced Heart Failure 2The Journal of Cardiac Failure Publishes Results From Celladon Corporation's First-in-Human Phase 1/2 Clinical Trial in Advanced Heart Failure 3SeqWright to Invest in LaserGen's Novel Lightning Terminators(TM) 2
(Date:5/21/2013)... Mass. , May 21, 2013 Royal ... CX50 xMATRIX, the world,s first portable ultrasound with Philips, ... Echo (ICE) capability. The CX50 xMATRIX with available Live ... Paris at the EuroPCR, official meeting ... May 21-24. Since its launch in 2012, ...
(Date:5/20/2013)... University of Minnesota Medical School researchers from the ... the University,s Brain Tumor Program, have developed a new ... that allow them to discover new genes and gene ... was published this week in the journal Nature ... researchers in the lab of David Largaespada, Ph.D., professor ...
(Date:5/20/2013)... New research suggests that a compound abundant in ... escape death. , By altering a very specific ... cells into normal cells that die as scheduled. , ... a process that would cause them to die on ... This study in cells, led by Ohio State University ...
Breaking Biology News(10 mins):Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2U of M researchers develop model for better testing, targeting of MPNST 2The compound in the Mediterranean diet that makes cancer cells 'mortal' 2The compound in the Mediterranean diet that makes cancer cells 'mortal' 3
... expert in the design of low-rise buildings for ... at the Annual Conference of Construction Specifications Canada ... Taher, a university lecturer in NJIT,s College of ... engineer, http://www.njit.edu/news/experts/taher.php . Construction Specifications Canada ...
... release is available in German . ... the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is to establish ... the appropriate Grants Committee in Bonn. The new institutions will ... years, during which time they will receive total funding of ...
... 19 May 2011. The research vessel Polarstern of the ... the Helmholtz Association will arrive back at its homeport ... May. Nearly 200 researchers from institutes in 15 countries ... conducted measurements showing that warming of the water in ...
Cached Biology News:Better buildings for extreme climates will be focus of researcher's talk 2DFG establishes 18 new research training groups 2DFG establishes 18 new research training groups 3DFG establishes 18 new research training groups 4DFG establishes 18 new research training groups 5DFG establishes 18 new research training groups 6DFG establishes 18 new research training groups 7DFG establishes 18 new research training groups 8DFG establishes 18 new research training groups 9DFG establishes 18 new research training groups 10Research ship Polarstern returns from Antartica 2Research ship Polarstern returns from Antartica 3
Monoclonal mouse antibody for immunihistology, clone AD12, Isotype IgG 1, purified, specific for rat pyruvatekinase type L, no cross-reactivities with other pyruvate kinase isoenzymes have been obser...
Control primers and template for 5kb and 15 kb products....
The Lambda Control Kit contains lambda DNA and two 25mer primers, which can be used to amplify a 500bp fragment. The lambda DNA is purified by CsCl gradient centrifugation and organic extraction foll...
... Klein Taq is a derivative of Taq ... truncated Thermus aquaticus DNA polymerase. Expressed from ... initiates at Met236, bypassing the 5'-3' exonuclease ... enzyme reveals a highly active and even ...
Biology Products: